These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6140343)

  • 1. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study.
    Brincat M; Magos A; Studd JW; Cardozo LD; O'Dowd T; Wardle PJ; Cooper D
    Lancet; 1984 Jan; 1(8367):16-8. PubMed ID: 6140343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of subcutaneous hormone implants during climacteric.
    Cardozo L; Gibb DM; Tuck SM; Thom MH; Studd JW; Cooper DJ
    Maturitas; 1984 Mar; 5(3):177-84. PubMed ID: 6727691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy.
    Panay N; Versi E; Savvas M
    BJOG; 2000 Aug; 107(8):1012-6. PubMed ID: 10955434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric.
    Montgomery JC; Appleby L; Brincat M; Versi E; Tapp A; Fenwick PB; Studd JW
    Lancet; 1987 Feb; 1(8528):297-9. PubMed ID: 2880114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term hormone implant therapy--hormonal and clinical effects.
    Barlow DH; Abdalla HI; Roberts AD; Al Azzawi F; Leggate I; Hart DM
    Obstet Gynecol; 1986 Mar; 67(3):321-5. PubMed ID: 3945443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal oestrogen replacement therapy with subcutaneous oestradiol implants.
    Suhonen S; Sipinen S; Lähteenmäki P; Laine H; Rainio J; Arko H
    Maturitas; 1993 Mar; 16(2):123-31. PubMed ID: 8483424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of hormone implants for climacteric symptoms.
    Cardozo L; Gibb DM; Studd JW; Tuck SM; Thom MH; Cooper DJ
    Am J Obstet Gynecol; 1984 Feb; 148(3):336-7. PubMed ID: 6695979
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
    Buckler H; Al-Azzawi F;
    BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women.
    Appleby L; Montgomery J
    Br Med J (Clin Res Ed); 1987 May; 294(6584):1417-8. PubMed ID: 3109683
    [No Abstract]   [Full Text] [Related]  

  • 10. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results.
    Burger HG; Hailes J; Menelaus M; Nelson J; Hudson B; Balazs N
    Maturitas; 1984 Dec; 6(4):351-8. PubMed ID: 6442755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy.
    Buckler HM; Kalsi PK; Cantrill JA; Anderson DC
    Clin Endocrinol (Oxf); 1995 May; 42(5):445-50. PubMed ID: 7621560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome.
    Magos AL; Brewster E; Singh R; O'Dowd T; Brincat M; Studd JW
    Br J Obstet Gynaecol; 1986 Dec; 93(12):1290-6. PubMed ID: 3801360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women.
    Burger H; Hailes J; Nelson J; Menelaus M
    Br Med J (Clin Res Ed); 1987 Apr; 294(6577):936-7. PubMed ID: 3107663
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial.
    Jensen J; Christiansen C
    Maturitas; 1983 Aug; 5(2):125-33. PubMed ID: 6415364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma oestrone, oestradiol and gonadotrophin concentrations in postmenopausal patients treated with oestradiol or with a combination of oestradiol and oestriol.
    Sipinen S
    Ann Clin Res; 1979 Oct; 11(5):172-8. PubMed ID: 121048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women.
    Selby PL; Peacock M
    Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1337-9. PubMed ID: 3098341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo.
    Crona N; Samsioe G; Lindberg UB; Silfverstolpe G
    Maturitas; 1988 Mar; 9(4):303-8. PubMed ID: 3288845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.